| Reactive oxygen species: a breath of life or death? JP Fruehauf, FL Meyskens Jr Clinical Cancer Research 13 (3), 789-794, 2007 | 1157 | 2007 |
| Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. E Mechetner, A Kyshtoobayeva, S Zonis, H Kim, R Stroup, R Garcia, ... Clinical cancer research: an official journal of the American Association …, 1998 | 401 | 1998 |
| Redox regulation in human melanocytes and melanoma FL Meyskens Jr, P Farmer, JP Fruehauf Pigment cell research 14 (3), 148-154, 2001 | 264 | 2001 |
| Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer MY Su, YC Cheung, JP Fruehauf, H Yu, O Nalcioglu, E Mechetner, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2003 | 218 | 2003 |
| Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors BI Rini, JH Schiller, JP Fruehauf, EEW Cohen, JC Tarazi, B Rosbrook, ... Clinical Cancer Research 17 (11), 3841-3849, 2011 | 216 | 2011 |
| BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma KB Kim, JA Sosman, JP Fruehauf, GP Linette, SN Markovic, ... Journal of Clinical Oncology 30 (1), 34, 2012 | 207 | 2012 |
| Prediction of drug response in breast cancer using integrative experimental/computational modeling HB Frieboes, ME Edgerton, JP Fruehauf, FRAJ Rose, LK Worrall, ... Cancer research 69 (10), 4484-4492, 2009 | 163 | 2009 |
| Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture V Trapp, B Parmakhtiar, V Papazian, L Willmott, JP Fruehauf Angiogenesis 13, 305-315, 2010 | 141 | 2010 |
| Mathematical modeling of cancer progression and response to chemotherapy S Sanga, JP Sinek, HB Frieboes, M Ferrari, JP Fruehauf, V Cristini Expert review of anticancer therapy 6 (10), 1361-1376, 2006 | 135 | 2006 |
| Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study LM Randall, BJ Monk, KM Darcy, C Tian, RA Burger, SY Liao, WA Peters, ... Gynecologic oncology 112 (3), 583-589, 2009 | 132 | 2009 |
| The effect of lentinan on production of interleukin-1 by human monocytes JP Fruehauf, GD Bonnard, RB Herberman Immunopharmacology 5 (1), 65-74, 1982 | 129 | 1982 |
| Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels Y Tang, B Parmakhtiar, AR Simoneau, J Xie, J Fruehauf, M Lilly, X Zi Neoplasia 13 (2), 108-119, 2011 | 123 | 2011 |
| Independent association of angiogenesis index with outcome in prostate cancer R Mehta, A Kyshtoobayeva, T Kurosaki, EJ Small, H Kim, R Stroup, ... Clinical cancer research 7 (1), 81-88, 2001 | 123 | 2001 |
| The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature JF Reavey-Cantwell, RI Haroun, M Zahurak, RE Clatterbuck, RJ Parker, ... Journal of neuro-oncology 55, 195-204, 2001 | 121 | 2001 |
| Reactive oxygen species: an Achilles˘ heel of melanoma? JP Fruehauf, V Trapp Expert review of anticancer therapy 8 (11), 1751-1757, 2008 | 120 | 2008 |
| Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma J Fruehauf, J Lutzky, D McDermott, CK Brown, JB Meric, B Rosbrook, ... Clinical cancer research 17 (23), 7462-7469, 2011 | 119 | 2011 |
| Association of diastolic blood pressure (dBP)≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736) BI Rini, JH Schiller, JP Fruehauf, EE Cohen, JC Tarazi, B Rosbrook, ... Journal of Clinical Oncology 26 (15_suppl), 3543-3543, 2008 | 109 | 2008 |
| In vitro drug response and molecular markers associated with drug resistance in malignant gliomas JP Fruehauf, H Brem, S Brem, A Sloan, G Barger, W Huang, R Parker Clinical Cancer Research 12 (15), 4523-4532, 2006 | 106 | 2006 |
| Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients RW Holloway, RS Mehta, NJ Finkler, KT Li, CE McLaren, RJ Parker, ... Gynecologic oncology 87 (1), 8-16, 2002 | 106 | 2002 |
| Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. SW Grant, AS Kyshtoobayeva, T Kurosaki, J Jakowatz, JP Fruehauf Cancer detection and prevention 22 (3), 185-194, 1998 | 106 | 1998 |
